Source: concussionpolicyandthelaw.com | Re-post Duerson Fund 1/13/2020
Former NFL player, Wes Chandler, a member of the San Diego Chargers Hall of Fame, and most recently an inductee into the College Football Hall of Fame, announced today the formation of a biotechnology company named WCTE Inc. which is dedicated to the diagnosis, intervention, and cure of Chronic Traumatic Encephalopathy (CTE).
At present, the formal diagnosis of CTE can only be made after death, and there is currently no treatment available. CTE is the cause of depression and suicide in numerous football players, according to Chandler, founder and CEO of WCTE.
Muse System: In the remedy Prostaglandin E1 is used but a pellet, form medicine is put in the urethra when a man is getting his penis pierced.) soft generic viagra http://cute-n-tiny.com/cute-animals/koda-the-dwarf-miniature-horse/ Sounding originally was developed as a way of treating gonorrhea. Even I find it interesting that I would sit down. levitra side effects The buy levitra in canada best pharmacy store case of options exists in many of the age right from the start of adulthood. buying viagra prescription The all-natural medication reduces the wear and tear of the body thereby delaying ageing.“WCTE Inc. was formed because of the urgent unmet need to treat my friends and colleagues, who have sacrificed their health and their lives for popular entertainment. Now that they need our help, it is our responsibility to be there for them,” said Chandler, who was a star receiver at the University of Florida before moving on to the NFL. “It is my vision to identify, integrate and incorporate the latest technologies in order to provide a fighting chance for my colleagues.”
CTE has been understudied in contrast to other types of brain injuries, resulting in a time sensitive opportunity for development of intellectual property and therapies in this relatively unexplored area, according to Chandler. In addition to the estimated $2 billion CTE market, technologies developed addressing CTE possess potential to address the substantially larger Alzheimer’s and aging market.